TLX (Telix Pharmaceuticals) Dividends Received: $0.0 Mil (TTM As of Dec. 2025)


TLX Telix Pharmaceuticals Ltd TLX
50 GF Score
Price $11.88
GF Value $30.50
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Dividends Received?

Telix Pharmaceuticals TLX +0.17% 50 Dividends Received is $0.0 Mil as of Dec. 2025. GuruFocus rates TLX with a GF Score™ of 50/100 and a GF Value™ of $30.50 (Possible Value Trap). The stock has 6 warning signs investors should review.

Telix Pharmaceuticals's Dividends Received for the six months ended in Dec. 2025 was $0.0 Mil.

Telix Pharmaceuticals's Dividends Received for the trailing twelve months (TTM) ended in Dec. 2025 was $0.0 Mil.

Telix Pharmaceuticals Dividends Received Related Terms

Telix Pharmaceuticals Dividends Received Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's Dividends Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals Dividends Received Chart

Telix Pharmaceuticals Annual Data
Trend Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividends Received
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividends Received Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TLX
50GF Score
Telix Pharmaceuticals Ltd TLX
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals Dividends Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Dividends Received represents dividend received on the investment in the direct cash flow method.

Dividends Received for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividends Received →
What does a Dividends Received of $0.0 Mil mean?
Telix Pharmaceuticals (TLX) has a Dividends Received of $0.0 Mil as of Dec. 2025. Dividends Received represents dividend received on the investment in direct cash flow method. View historical data for Telix Pharmaceuticals and its competitors.
Is Telix Pharmaceuticals' Dividends Received too high?
Telix Pharmaceuticals' current Dividends Received is $0.0 Mil. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Dividends Received compare to VRTX and REGN?
Telix Pharmaceuticals' Dividends Received of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividends Received for a Biotechnology company?
A good Dividends Received depends on the Biotechnology industry context. However, Dividends Received should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividends Received mean?
A high Dividends Received can signal that a stock is expensive relative to its fundamentals. Dividends Received represents dividend received on the investment in direct cash flow method. View historical data for Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current Dividends Received is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $30.50, compared to a current price of $11.88 — trading 61% below its estimated fair value. The current Dividends Received is $0.0 Mil. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividends Received calculated?
Dividends Received is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current Dividends Received is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (TLX) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $11.88 is trading 61% below its estimated GF Value™ of $30.50. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLX:

  • Dividends Received: $0.0 Mil
  • GF Value™: $30.50 vs. price of $11.88 (61% below fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score

Get the complete analysis for TLX

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.88
Price
$30.50
GF Value